Filing Flows

Filing Flows › Companies › Neuroone Medical Technologies › Cash flow

Neuroone Medical Technologies cash flow, quarter by quarter

Latest: Q3 FY26 · from the cash-flow statements filed with the SEC

Free cash flow−$1.1M in Q3 FY26 · −$7.2M over twelve months

Operating cash flow−$1.1M
Capital spending−$20K
Free cash flow−$1.1M
Cash conversion cycle216 days

Analysis

In Q3 FY26, Neuroone Medical Technologies generated −$1.1M of operating cash flow and spent $20K on capital projects, leaving free cash flow of −$1.1M. That is $406K more than in Q3 FY25 (−$1.5M).

Over the twelve months to Jun 30, 2026, operating cash flow was −$7.1M; the largest uses were operating cash flow ($7.1M), capital spending ($110K), taxes on employees’ shares ($70K); besides operations, cash came from other financing ($1.2M); the cash balance fell by $6.0M.

Operating cash flow was −$1.1M against net income of −$2.0M. The largest differences: receivables +$798K, accrued liabilities +$361K, stock-based pay +$353K.

Its cash conversion cycle was 216 days (receivables 69 + inventory 253 − payables 106).

Free cash flow

Neuroone Medical Technologies: free cash flow by quarterNeuroone Medical Technologies: free cash flow by quarter−$2.7MQ4 FY24$184KQ1 FY25−$59KQ2 FY25−$1.5MQ3 FY25−$1.5MQ4 FY25−$3.2MQ1 FY26−$1.4MQ2 FY26−$1.1MQ3 FY26
Operating cash flow less capital spending.
Neuroone Medical Technologies: operating cash flow against capital spendingNeuroone Medical Technologies: operating cash flow against capital spendingOperating cash flowCapital spending−$2.7M$37KQ4 FY24$208K$24KQ1 FY25−$56K$3KQ2 FY25−$1.5M$44KQ3 FY25−$1.5M$11KQ4 FY25−$3.1M$41KQ1 FY26−$1.3M$39KQ2 FY26−$1.1M$20KQ3 FY26
Latest (Q3 FY26): Operating cash flow −$1.1M, Capital spending $20K.

Capital allocation, year by year

Neuroone Medical Technologies: where the cash came from (up) and went (down), by fiscal yearNeuroone Medical Technologies: where the cash came from (up) and went (down), by fiscal yearOperating cash flowShares issuedAsset salesCapital spendingFY21: Operating cash flow −$8.6MFY21: Shares issued $10KFY21: Capital spending −$67K$10KFY21FY22: Operating cash flow −$7.5MFY22: Capital spending −$275KFY22FY23: Operating cash flow −$12.9MFY23: Shares issued $2.6MFY23: Asset sales $8KFY23: Capital spending −$384K$2.6MFY23FY24: Operating cash flow −$11.0MFY24: Shares issued $837KFY24: Capital spending −$120K$837KFY24FY25: Operating cash flow −$2.8MFY25: Capital spending −$82KFY25
Over these 5 years operating cash flow totalled −$42.9M; the largest uses were operating cash flow ($42.9M) and capital spending ($928K). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$2.0M
Debtnone
Net cash$2.0M
Cash runway3 months

Neuroone Medical Technologies is burning cash: its operations consume cash, a free cash flow of −$7.2M a year at the current rate against $2.0M of cash and investments: a runway of about 3 months before any new financing.

Where the cash came from and went

Neuroone Medical Technologies: sources (+) and uses (−) of cash, Q3 FY26Neuroone Medical Technologies: sources (+) and uses (−) of cash, Q3 FY26Operating cash flow−$1.1MCash drawn (+) / kept (−)$756KShares issued$359KCapital spending−$20KOther financing−$11KTaxes on employees’ shares−$3K
Neuroone Medical Technologies: sources (+) and uses (−) of cash, TTM to Q3 FY26Neuroone Medical Technologies: sources (+) and uses (−) of cash, TTM to Q3 FY26Operating cash flow−$7.1MCash drawn (+) / kept (−)$6.0MOther financing$1.2MCapital spending−$110KTaxes on employees’ shares−$70K

From profit to cash

Neuroone Medical Technologies: net income to operating cash flow, Q3 FY26Neuroone Medical Technologies: net income to operating cash flow, Q3 FY26Net income−$2.0MDepreciation & amortization$47KStock-based pay$353KReceivables$798KInventory−$192KPayables−$33KAccrued liabilities$361KPrepaid and other assets−$35KOperating cash flow−$1.1M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.
QuarterReceivable daysInventory daysPayable daysCash conversion cycle
Q3 FY2669253106216
Q2 FY2611019477228
Q1 FY266213554143
Q2 FY2587275121242
Q1 FY253615661131
Q4 FY249915526271025

Every quarter

QuarterOperating cash flowCapital spendingShares issuedCash drawn (+) / kept (−)Free cash flow
Q3 FY26−$1.1M−$20K$359K$756K−$1.1M
Q2 FY26−$1.3M−$39K—$758K−$1.4M
Q1 FY26−$3.1M−$41K—$3.0M−$3.2M
Q4 FY25−$1.5M−$11K—$1.5M−$1.5M
Q3 FY25−$1.5M−$44K$9.2M−$6.7M−$1.5M
Q2 FY25−$56K−$3K—−$186K−$59K
Q1 FY25$208K−$24K—$326K$184K
Q4 FY24−$2.7M−$37K−$4.2M$160K−$2.7M

Neuroone Medical Technologies: income statement and cash flow

Neuroone Medical Technologies, Q3 FY26: revenue $2.0M (+16% year over year), operating margin -122.9%. The chart follows the revenue to costs, profit and cash.

Neuroone Medical Technologies: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.